• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Inspections, Compliance, Enforcement, and Criminal Investigations

  • Print
  • Share
  • E-mail

Mount Auburn Hospital 16-Jul-02

Department of Health and Human ServicesDepartment of Health and Human Services            Public Health Service


Food and Drug Administration
New England District
One Montvale Avenue
Stoneham, Massachusetts 02180
(781) 596-7700
FAX: (781)596-7896

WARNING LETTER
NWE-24-02W
VIA FEDERAL EXPRESS
July 16, 2002

Jeanette G. Clough
President / CEO
Mount Auburn Hospital
330 Mount Auburn Street
Cambridge, MA 02238

Dear Ms. Clough:

We are writing to you because on May 28, 2002, your mammography facility, located at Mount Auburn Hospital was inspected by a representative of the Commonwealth of Massachusetts, acting on behalf of the Food and Drug Administration (FDA). This inspection revealed a serious regulatory problem involving the mammography at your facility.

Under a United States Federal law, the Mammography Quality Standards Act of 1992 (MQSA), 42 U.S.C. 263b, your facility must meet specific requirements for mammography. These requirements help protect the health of women by assuring that a facility can perform quality mammography. The inspection revealed the following significant violation, which is included on the MQSA Facility Inspection Report that your facility received at the close of the inspection:

Your records revealed that image quality evaluation tests, using an FDA-approved phantom (Phantom QC) were missing for at least 4 weeks for both unit 2, [redacted] in Room 2, and unit 3, 900.12(e)(2)(i), (ii), (iii) & (iv)] During the inspection, the inspector observed that there were no weekly phantom quality control charts or films between the date of your last inspection, April 11, 2001, and July 8, 2001. Your records showed that mammography examinations were performed during that time period.

Because this violation may be symptomatic of serious underlying problems that could compromise the quality of mammography at your facility, it represents a violation of the law that may result in FDA initiating regulatory action without informal notice to you. These actions include, but are not limited to, placing your facility under a Directed Plan of Correction, charging your facility for the cost of on-site monitoring, seeking civil money penalties up to $10,000 for each failure to substantially comply with, or each day of failure to substantially comply with, the MQSA standards, seeking suspension or revocation of your facility?s FDA certificate, or seeking a court injunction against performing further mammography. (See 42 U.S.C. 263b(h)-(j)).

It is necessary for you to act on this matter immediately. Please explain to this office in writing within fifteen (15) working days from the date you received this letter:

- the specific steps you have taken to correct all of the violations noted in this letter;

- each step your facility is taking to prevent the recurrence of similar violations;

- a copy of your written procedures for performing the weekly phantom QC test, including the criteria for a passing phantom image and procedures for taking and documenting corrective action when the phantom QC test fails for any of the required parameters

- equipment settings (including technique factors) raw test data, and calculated final results where appropriate; and

  • sample records that demonstrate proper record keeping procedures for the results of such testing. (Note: Patient names or identification should be deleted from any copies submitted)

Please submit your response to: Karen N. Archdeacon, Compliance Officer, New England District Office, at the address noted above.

You should also send a copy of your response to:

Mr. Robert Hallisey
Radiation Control Program
Department of Public Health
174 Portland Street, 5th Floor
Boston, MA 02 114

In addition, your response should address the following finding that was listed on the inspection report provided to you at the close of the inspection:

There was no documentation to show that the radiologic technologist, [redacted] met the minimum requirement of having performed at least 200 mammography examinations in 24 months. Your records showed that [redacted], had performed 147 mammography examinations during the prior 24 month period. [21 CFR 900.12(a)(2)(iv)]

Finally, you should understand that there are many FDA requirements pertaining to mammography. This letter pertains only to findings of your inspection and does not necessarily address other obligations you have under the law. You may obtain general information about all of FDA?s requirements for mammography facilities by contacting the Mammography Quality Assurance Program, Food and Drug Administration, P.O. Box 6057, Columbia, MD 21045-6057 (1-800-838-7715) or through the Internet at http://www.fda.gov.

If you have specific questions about mammography facility requirements you may contact Michael Leal, MQSA Auditor at (508) 793-0422. If you have any other questions concerning this matter, please contact Ms. Archdeacon at (781) 596-7707.

Sincerely yours,

/s/

Gail T. Costello

District Director